Get the Stockscreener App
50.18
0.22%
-0.11
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $50.18, with a volume of 12.33M.
It is down -0.22% in the last 24 hours and down -0.16% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$50.29
Open:
$50.53
24h Volume:
12.33M
Relative Volume:
0.75
Market Cap:
$222.97B
Revenue:
$46.69B
Net Income/Loss:
$15.29B
P/E Ratio:
14.62
EPS:
3.4329
Net Cash Flow:
$9.25B
1W Performance:
+4.85%
1M Performance:
-0.16%
6M Performance:
-38.09%
1Y Performance:
-53.80%
1-Day Range:
$49.91
$50.75
1-Week Range:
$46.08
$50.75
52-Week Range:
$43.08
$109.88
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
50.18 | 223.46B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch - Benzinga
Novo Nordisk (NVO) Experiences Muted Sentiment From Analysts - Finviz
Novo Nordisk (NVO) Partners With Indian Health-Tech Startup - Finviz
Argus Downgrades Novo Nordisk A/S (NVO) to Hold From Buy - Finviz
Analysts See Upside In Novo Nordisk A/S (NVO) Driven By Diabetes And Obesity Trends - Finviz
Why Novo Nordisk Stock Was Melting on Monday - Finviz
Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know. - Finviz
Why Novo Nordisk Stock Just Hit a 4-Year Low - Finviz
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 - Finviz
J.P. Morgan Reiterates a Buy Rating on Novo Nordisk (NVO) - Finviz
Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B - TradingView
European Drugmakers And Banks Put ADRs In The Green - Finimize
NVONovo Nordisk ADR Earnings - Finviz
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy - Sahm
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month - Sahm
Did Pfizer Just Say "Checkmate" to Novo Nordisk? - Finviz
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says - Sahm
European ADRs Stay Put As Novo Nordisk Slides - Finimize
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients - Sahm
Novo Nordisk (NVO) is Trending On RedditHere's Why - Finviz
Novo Nordisk's Wegovy Shows Weight Loss-Independent Liver Benefits in MASH Trial Data - Finviz
Here's Why Novo Nordisk Stock Popped Today - Finviz
Why Novo Nordisk Stock Sank 5.6% Today - Finviz
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk - Sahm
Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025) - ts2.tech
Novo Nordisk's Blockbuster Weight-Loss Drug Flops In Alzheimer's Trial - Sahm
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? - Finviz
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates - ts2.tech
Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer's - Sahm
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):